



Project Number: 610472

A CANcer Development mOnitor

Specific Targeted Research Project

Information Society Technologies

Deliverable D6.11: End of year 2 version of roadmap for use and dissemination of foreground. Section A (Public)

Due date of deliverable: **29th February 2016**

Actual submission date: **16th April 2016**

Start date of project: 2014-01-01

Duration: 3 Years

Organisation name of lead contractor for this deliverable: **UVEG**

Organisation names of contributors for this deliverable: All

Revision **[1.0]**

Project co-funded by the European Commission within the Seventh Framework Programme		
Dissemination Level		
PU	Public	X
PP	Restricted to other programme participants (including the Commission Services)	
RE	Restricted to a group specified by the consortium (including the Commission Services)	
CO	Confidential, only for members of the consortium (including the Commission Services)	

1 Document History

Version: 1
Lead author: UVEG (Public), GILUPI (Confidential)
Authors: All
Date: 20/04/16
Changes: None, first version
Internal approval: 20/04/16
Delivery to the EC: 14/04/16

2 Executive Summary

The purpose of the document is to report how the knowledge generated during the project lifetime, or foreground has been used both through dissemination, and use, or exploitation. In this way, the EC and its review team can see the progress being made in the impact of the project and provide recommendations as appropriate, principally so that new technologies and/or products with Freedom To Operate (FTO) and Unique Selling Points (USP) may be identified and then commercialised shortly after the project's end.

The report is laid out according to the tasks defined in WP6 as follows: T6.3: Elaboration of roadmap for use and dissemination of foreground. It consists of two parts:

Section A: describing the dissemination measures, including any scientific publications relating to foreground. **Its content can be made available in the public domain** thus demonstrating the added-value and positive impact of the project on the European Community.

Section B: This section specifies the exploitable foreground and provides the plans for exploitation. **This section must be kept confidential** and must be treated as such by the Commission. This section is also gathered as a section in D6.5, in order to provide a logical structure that facilitates the review team their tasks.

Within the first part we include, amongst others, plans for disseminating scientific and technological information and identifies a priori potential users' forum. This plan will be implemented and commented upon throughout the project lifetime, which will be described in Deliverables D6.11 (M26) and D6.16 (M44). Dissemination of project results is carried out by consortium members. This include participation in workshops, conferences, EC related events, standardisation bodies, etc. CanDo members will participate and share information and resources with on-going R&D activities or entities, such as NoEs, IPs or any other horizontal network.

The second part is described in Section B in a separate document.

3 Deliverable structure

Table of Contents

1	DOCUMENT HISTORY	2
2	EXECUTIVE SUMMARY	2
3	DELIVERABLE STRUCTURE	2
4	SECTION A – DISSEMINATION (FOR PUBLIC KNOWLEDGE)	4
4.1	SETUP OF CANDO WEBSITE	4
4.2	CREATION OF PROMOTIONAL MATERIAL.....	4
4.2.1	Project leaflet	4
4.2.2	Poster.....	5
4.2.3	A short presentation.....	6
4.2.4	A newsletter	6
4.3	DISSEMINATION AMONG OTHER FP7 RTD PROJECTS.....	6
4.4	GENERAL PUBLICITY OF THE PROJECT.....	7


4.4.1	Press releases	7
4.4.2	The user forum.....	8
4.4.3	"Student days" and "Open days"	8
4.4.4	Other dissemination events	8
4.5	COMMUNICATIONS TO SCIENTIFIC JOURNALS AND CONFERENCES/WORKSHOPS	8
4.5.1	Scientific Publications	¡Error! Marcador no definido.
4.5.2	Conference communications	9
4.5.3	Peer reviewed scientific publications	9
4.6	INTERNAL DISSEMINATION	10
4.7	CONTRIBUTIONS TO STANDARDS.....	10
4.8	CONTRIBUTION TO POLICY DEVELOPMENTS	10
4.9	RISK ASSESSMENT AND RELATED COMMUNICATION STRATEGY	10
5	CONCLUSIONS	10

4 Section A – Dissemination (for public knowledge)

This section includes a list of both planned and realised dissemination activities (publications, conferences, workshops, web, press releases, flyers, etc) in free text format. In addition, a list of scientific (peer reviewed) publications is provided.

4.1 Setup of CanDo website

The interactive webpage, <http://www.fp7cando.eu>, shown below, contains all the public information related with the project advances, which are actualized monthly. Additionally, it has an intranet access for the project partners and for the reviewers, supplied by the University of Valencia. In this intranet are saved all the documents related to the project (deliverables, review reports, financial, etc.).



The web page is monthly actualized with the last information concerning newsletters, flyers, publications, etc.

4.2 Creation of promotional material

During the project we aim to publicize the project and its results through the creation and distribution of promotional material available for broader distribution at key events and through a newsletter to a regularly updated database of contacts (= the user forum, see section 4.2.4).

The first set of promotional material created by M6 (D6.2) was updated in M14 (D6.8). Further updates are to follow in M26 (D6.13) and M38 (D6.18). The promotional material consists of a project leaflet, a poster, a short presentation and a newsletter (to the CIG). UVEG leads this work, with active assistance of all the project partners.

4.2.1 Project leaflet

The first project leaflet, created and professionally printed (400 copies) by M6, contained just general information about the project, its objectives and its partners. Two errors were identified at the M9

review and have been corrected. The updated version in M14 (550 professionally printed copies) focussed on achievements over the first 14 months as well as a featurette on the GILUPI CellCollector®. The leaflets are also available for download via the CanDo website. A new leaflet is under preparation and it will be published within this month (M26), following the project agenda.

4.2.2 Poster

A first poster was created, printed and used by the partners as of M6. The first poster contains general information about the project, its objectives and its partners. The 'stock' poster includes the new logo design. Here is a copy of the actual poster.


A CANcer Development mOnitor

Funded by 4M€ from the FP7 ICT programme of the EC.




fp7.cando.eu

Pancreatic Cancer




Pancreatic **CAN**cer diagnosis is currently achieved using a set of methods: computed tomography (CT), magnetic resonance (MR), etc., which aside from being costly and unpleasant for the patients are not specific for pancreatic **CAN**cer nor are they designed for **early diagnosis**, making a **correct and timely diagnosis** challenging.

CanDo platform




The **CanDO** platform will consist of **modular components** and systems that will be integrated into a economical and disposable two cartridge system with different lab-on-a-chip technologies, designed to capture in **parallel in-vivo CTCs**, that is not limited to **blood samples** volume, and **in-vitro**.



CellCollector™
for in vivo CTC
collection

Cartridge I

Inertial microfluidics



Cross flow
membrane cell
trapping,
*courtesy of
Microfluidic
ChipShop*

EpCAM CTC capture


SERS analysis

Cartridge II

RNA extraction

RNA amplification and preparation


Si nanophotonic
IC, *courtesy of
IMEC*



Nanophotonic biosensor


CanDo consortium

CanDo will develop a **point of care** (PoC), rapid and economical diagnostic platform capable of isolation and concentration determination of CTCs in peripheral blood as well as **molecular characterization** for **early diagnosis** of **pancreatic cancer**.



4.2.3 A short presentation

A short presentation of 7 pages was created and updated. It serves as a basis for CanDo oral dissemination events for incorporation into more detailed presentations or for use ad hoc at opportunities where the partners can present their on-going work. Here is the image of page 2, where a summary of the project and the information on the consortium has been included.



- 7 European research and/or academic centres and 3 commercial enterprises have joined together to form a new European research consortium in a project called "CanDo" or a "CANcer Development mOnitor".

The European Union supports the consortium during a three-year period with 4M Euros through its Seventh Framework Programme. CANDO, will be led by the University of Valencia.

2

4.2.4 A newsletter

The M6 newsletter created and distributed to the CanDo User Group via email was followed up by an updated version in M14 with highlights of technical results to date in the project and a feature on GILUPI and the GILUPI CellCollector®. All of the above promotional material is available for download via the CanDo website. Further newsletters will be created and distributed to the CIG in months M26 and M38, see also section 2.4.2. The new newsletter is under preparation (see D6.13) and it will be uploaded within M26, following the agenda.

4.3 Dissemination among other FP7 RTD projects

In M6 a cooperation agreement was signed between the FP7 Miracle and FP7 CanDo consortia for the exchange of know-how (D6.19). In this way a critical mass of know-how could be built up in these key areas, allowing FP7 CanDo to avoid the same mistakes from FP7 Miracle and in general allow greater advances for the same given resources. In M8, initial information exchange events took place on a limited basis. Since then CanDo had been awaiting an executive summary of the exploitation report of FP7 Miracle, which was requested as a starting point for the exploitation plan of CanDo (T6.4) as according to page 104 of the current CANDO DoW. Upon consultation with both Bayer and Gilupi the Project Committee Meeting convened in M12 in Jena decided that no advantage would

be gained from receiving information from Miracle and so the collaboration has been terminated. MFChipChop had a meeting in Karlsruhe in M23 to exchange information with the partners of project SAVVY. There was a general presentation of the project. The meeting was in English. Fifteen persons attended the meeting. Finally, in M22 there was a meeting with the partners of project MNBS. There were 10 participants and the meeting was in English. There are two more meetings planned for 2016.

Table: Dissemination events to other FP7 RTD projects

Date	Event	Responsible CanDo partner
M23	Presentation of the project to the FP7 project Savvy	MCFS
M22	Presentation of CanDo to the FP7 project MNBS	Gilupi
planned for 2016	Joint workshop between CanDo and FP7 CareMore	SU
planned for 2016	Presentation of the project to the FP7 project Hemospec	IPHT

4.4 General publicity of the project

Further publicity will take place through the *dissemination of CanDo research results to the non-scientific/technical media at large* (eg. newspapers, magazines, TV, periodicals) and raising of public awareness for the project and interest in photonic technologies at "student days", "open days", "girls days".

4.4.1 Press releases

Whenever a good opportunity presents itself, CanDo will disseminate its results via the larger press. These opportunities will either be pursued actively, e.g. when critical results are being obtained, or will occur ad-hoc when the partners are contacted by the press in conjunction with the general research activities.

- ✓ Several press releases were made in the past. No activity in this field was taking during year 2. We plan to undertake the activity during the y3 period, since we will have results with more impact which can be shown in press releases or via internet news.

Date	Press release content	Responsible partner
M3	Project start: http://www.ikerlan.es/en/news/press-notice/labonachip-to-detect-spread-of-pancreatic-cancer-in-5-hours	Ikerlan
M6	Project start: http://www.ipht-jena.de/en/news/read-more/back/2/newsdate/2014/06/12/analyse-labor-in-chip-groesse-zur-krebsfrueherkennung.html	IPHT
M7	Project start: http://www.pcu.es/es/news-room/noticias-destacadas/2014/Nano-biotecnolog-as http://www.uv.es/uvweb/universitat/ca/llista-noticies/universitat-valencia-lidera-projecte-europeu-deteccio-precoc-cancer-pancrees-1285846070123/Noticia.html?id=1285914820053	UVEG
M9	http://www.gilupi.com/de/pdf/VistapreviadeDraftPresseleaseCanDo_pancreaticcancerDAY_2014_11_12_FINAL.pdf	GILUPI

4.4.2 The user forum

CanDo identified a user forum, the CanDo Interest Group (CIG) that contains key players and experts from throughout the value chain: Industry (most of them from European companies), governmental agencies and academia. The user group currently consists of >150 entities. The first newsletter was distributed to this group at M6 and the second in M14. The third newsletter will be also distributed to the CIG within this month.

4.4.3 "Student days" and "Open days"

All partners will identify a suitable event in which they will disseminate the CanDo project and its results to the broader public.

Date	Led by CanDo partner	Event/place	Language	Type and size of audience	Topic addressed/aim
M17	UVEG	Expociencia 2015, Universidad de Valencia	Spanish	students, researcher, 600	Science in the Scientific Park
Planned	SLL_KU	To be defined			
Planned	Bayer	To be defined			
Planned	IK4-Ikerlan	To be defined			
Planned	KTH	To be defined			
M22	SU	SciLifeLab day (Lost and found in life science)	English	Ph. D. Students, researchers, 500	
M19	MFCS	Summer School	English	Ph. D. Students,	
Planned	IPHT	To be defined			
Planned	IMEC	To be defined			
Planned	Gilupi	To be defined			
Seminar	SU	JNI Oncology lectures, EMC Rotterdam, the Netherlands	English	researchers, 70	cancer

4.4.4 Other dissemination events

Date	Event	Responsible CanDo partner
M25	Photonics West 2016	UVEG
M15	PhotOptics 2015	UVEG
M18	Laser World of Photonics 2015	IPHT
M21	LoC WC	MCFS
M33	LoC WC	MCFS

4.5 Communications to scientific journals and conferences /workshops

The project research results obtained will be either protected by patenting and/or published at international conferences, EU-workshops and refereed journals, such that dissemination activities to the scientific community and the European Diagnostics industry as follows:

4.5.1 Conference communications

ID	Planned / actual dates	Type: Conference	Type of audience	Venue
1	M17	2nd Bioanalytical Sensors Conference	Researchers, commercial	Berlin
2	M18	Advances in Functional Materials	Researchers	New York
3	M19	International Conference of Advanced Vibrational Spectroscopy	Researchers, commercial	Vienna
4	M21	European Conference of the Spectroscopy of Biological Macromolecules	Researchers	Bochum
5	M22	Computational plasmonics	Researchers	Lausanne
6	M24	ICNM	Researchers	Taj, India
7	M25	Personalized Medicine World Conference	Researchers, commercial	Silicon Valley
8	M26	SPIE Photonics West	Researchers, commercial	San Francisco
9	M26	SPIE Photonics West	Researchers, commercial	San Francisco

4.5.2

4.5.3

4.5.4 Peer reviewed scientific publications

Title	Main author	Title of the Periodical or de Series	Publisher	Year of publication
An advance towards the synthesis of Ag nanorod arrays with controlled surface roughness for SERS substrates	M. Gómez-Gómez	MaterialsToday: Proceedings 3, 294-302	Springer	2016
Design and first applications of a flexible Raman micro-spectroscopic system for biological imaging	R. Kiselev	Biological Spectroscopy and Imaging 5, 115-117	IOP	2016
Applications of coherent Raman scattering microscopies to clinical and biological studies	IW Schie	Analyst 140, 3897-3908	RSC	2015
Developments in spontaneous and coherent Raman scattering microscopic imaging for biomedical applications	C Krafft	Chem. Soc. Reviews	RSC	2016
Rapid acquisition of mean Raman spectra of eukaryotic cells for a robust single cell classification	Schie, Iwan	Analyst, submitted	RSC	2016
Cell classification with low-resolution Raman spectroscopy (LRRS)	Schie, Iwan	J. Biophoton., submitted	Wiley	2016

We are conducting a series of 30-60 minute lectures to be held at each consortium meetings. The lectures contain a basic introduction in each of the many scientific and technical fields addressed within CanDo. The target audience will be the CanDo partners themselves AND interested researchers at the site of the meeting.

Date	Lecture title
Dec 2015	Comparison of capture efficacy
Nov-16	Comparison of clinical results
Feb-16	To be defined
TBA	Inertial separation
Planned	To be defined
Planned	Microfluidics technology and Fabrication methods
Planned	Microfluidics product development strategies
Planned	To be defined

4.6 Contributions to standards

Throughout the project, where necessary, the consortium will contribute to national and/or international standards.

4.7 Contribution to policy developments

In the eventuality that the project would have significant impacts on research or research-based policy development at regional, national or European level such details and policy process shall be detailed in the dissemination section of the periodic reports.

4.8 Risk assessment and related communication strategy

Any potential risks (real or perceived) for society/citizens associated with the project and the communication strategy adopted in this regard will be identified during the project and communicated to the corresponding group through the appropriate means.

5 Conclusions

Dissemination of foreground suitable for public knowledge has been outlined and will be later updated at M38.